Company news
Amplia Therapeutics Ltd. (ASX:ATX) news
Amplia Therapeutics Ltd. news releases on 6ix. Latest, Jun 28, 2019: Rights Issue Prospectus
Press releases — page 4
Rights Issue Prospectus
June 27, 2019
Dr John Lambert appointed as new CEO
June 24, 2019
Capital Raising for Clinical-Enabling Studies
June 12, 2019
Preliminary Final Report - Year Ended 31 March 2019
May 29, 2019
Appendix 4C - Quarterly Statement of Cash Flows
April 29, 2019
European Patent Completes IP Protection in Major Markets
March 31, 2019
Appendix 4C - December 2018 Quarter Cashflow Statement
January 28, 2019
App 4D Half Year Accounts 30 Sep 2018
November 28, 2018
Appendix 4C - quarterly
October 30, 2018
Response to ASX Query
August 14, 2018
Appendix 4C - June 2018 Quarter Cashflow Statement
July 30, 2018
European Patent Granted for Innates Drug Candidate AMP-886
July 22, 2018
Preliminary Final Report - Year Ended 31 March 2018
May 30, 2018
App 4C - March 2018 Quarterly Cash Flow Report
April 30, 2018
Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates
March 22, 2018
S&P DJ Indices Announces March Quarterly Rebalance
March 8, 2018
Appendix 4C - December 2017 Quarter
January 30, 2018
Half Yearly Report and Accounts - HY ending 30 Sep 2017
November 30, 2017
Appendix 4C - September 2017 Quarter Cashflows
October 29, 2017
Corporate Update
October 19, 2017
App 4C - Quarterly Statement of Cashflows - June 2017 Qtr
July 27, 2017
No Change in Trial Outcome Following Additional Analysis
July 20, 2017
Top-Line Results for Trial of MIS416
June 26, 2017
FDA Clearance - MIS416 Investigational New Drug Application
June 20, 2017
Preliminary Final Report - Year Ended 31 March 2017
May 30, 2017
Appendix 4C - March 17 Quarter Statement of Cash Flows
April 28, 2017
Completion of Phase 2B Trial of MIS416
April 19, 2017
Private Placement to raise Additional Working Capital
March 16, 2017
Phase 2B Trial of MIS416 on Schedule to Complete April 2017
February 27, 2017
IIL Panel Declines to Conduct Proceedings
February 19, 2017
Appendix 4C - Dec 2016 Quarter Statement of Cashflows
January 30, 2017
Response to Price Query
December 30, 2016
App 4D - Half Yearly Report and Accounts HY ended 30 Sep 16
November 29, 2016
Phase 2B Update - Patients Wanting Access to Drug Post Trial
November 6, 2016
Appendix 4C - Quarterly Cashflows Report - Sept 2016 Qtr
October 31, 2016
Clinical Trials Update - 2016 Bioshares Biotech Summit
August 1, 2016
Appendix 4C - quarterly - June 16 Qtr
July 29, 2016
Final Stage of Capital Raising Programme Completed
July 19, 2016
Rights Issue Booklet
June 9, 2016
Preliminary Final Report - YE 31 March 2016
May 31, 2016
Appendix 4C - Statement of Cashflows March 2016 Qtr
April 28, 2016
Clinical Trial Fully Enrolled and Strong Interest
April 12, 2016
Update on Innates Phase 2B trial and recent activities
March 30, 2016
Appendix 4C - Dec 2015 Quarterly Cash Flow Report
February 11, 2016
Appendix 4C - Quarterly Cash Flow Report Sept 15 Qtr
February 10, 2016